Skip to content

Supernus Pharmaceuticals SUPN Debt securities - current

Debt securities - current at other companies

Block logo
BlockXYZ
$462.61M+30.4%
Agilon Health logo
Agilon HealthAGL
$91.42M-60.3%
General Motors logo
General MotorsGM
$4.62B-33.3%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$199.37M-42.7%
Qualys, Inc. logo
Qualys, Inc.QLYS
$191.88M+27.7%
Nike logo
NikeNKE
$1.4B-22.0%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's debt securities - current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's debt securities - current?
Supernus Pharmaceuticals (SUPN) reported debt securities - current of $199.37M in Q1 2026.
How has Supernus Pharmaceuticals's debt securities - current changed year-over-year?
Supernus Pharmaceuticals's debt securities - current decreased by 42.7% year-over-year, from $347.74M to $199.37M.
What is the long-term trend for Supernus Pharmaceuticals's debt securities - current?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's debt securities - current has grown at a -21.2% compound annual growth rate (CAGR), from $368.21M to $180.22M.